Cytek Biosciences Inc (CTKB)vsStryker Corporation (SYK)
CTKB
Cytek Biosciences Inc
$4.31
-1.60%
HEALTHCARE · Cap: $588.89M
SYK
Stryker Corporation
$352.25
-1.20%
HEALTHCARE · Cap: $118.55B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 12277% more annual revenue ($25.27B vs $204.17M). SYK leads profitability with a 13.2% profit margin vs -36.2%. SYK earns a higher WallStSmart Score of 57/100 (C).
CTKB
Hold41
out of 100
Grade: D
SYK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+41.3%
Fair Value
$7.43
Current Price
$4.31
$3.12 discount
Margin of Safety
-57.3%
Fair Value
$224.01
Current Price
$352.25
$128.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 73.5% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Areas to Watch
Smaller company, higher risk/reward
ROE of -22.6% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Premium valuation, high expectations priced in
2.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CTKB
The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Price/Book.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap.
Bear Case : CTKB
The primary concerns for CTKB are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CTKB profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.
CTKB carries more volatility with a beta of 1.17 — expect wider price swings.
CTKB is growing revenue faster at 6.5% — sustainability is the question.
SYK generates stronger free cash flow (415M), providing more financial flexibility.
Bottom Line
SYK scores higher overall (57/100 vs 41/100). CTKB offers better value entry with a 41.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytek Biosciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, delivering innovative cell analysis solutions that advance research in immunology, cancer diagnostics, and drug development. The company leverages its proprietary technologies to meet the growing demand for precision in cellular analytics, positioning itself as a key player in the biotechnology sector. With a robust product portfolio and a commitment to exceptional customer support, Cytek is well-equipped to drive transformative discoveries, ultimately enhancing healthcare outcomes and addressing critical challenges in the life sciences.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?